UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.994-1005

2024

Volltextzugriff (PDF)

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4127-4157

2011

Volltextzugriff (PDF)

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.777-791

2019

Volltextzugriff (PDF)

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

Clinical cancer research, 2015-06, Vol.21 (12), p.2811-2819

2015

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4111-4126

2011

Volltextzugriff (PDF)

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer

Bioorganic & medicinal chemistry letters, 2013-04, Vol.23 (7), p.1945-1948

2013

Volltextzugriff (PDF)

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades

Trends in pharmacological sciences (Regular ed.), 2020-06, Vol.41 (6), p.390-408

2020

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model

Molecular cancer therapeutics, 2023-05, Vol.22 (5), p.679-690

2023

Volltextzugriff (PDF)

Interspecies evaluation of a physiologically based pharmacokinetic model to predict the biodistribution dynamics of dendritic nanoparticles

PloS one, 2023-05, Vol.18 (5), p.e0285798-e0285798

2023

Volltextzugriff (PDF)

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

British journal of pharmacology, 2021-02, Vol.178 (3), p.600-613

2021

Volltextzugriff (PDF)

A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models

The AAPS journal, 2023-06, Vol.25 (4), p.66-66, Article 66

2023

Volltextzugriff (PDF)

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Clinical cancer research, 2020-07, Vol.26 (14), p.3751-3759

2020

Volltextzugriff (PDF)

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors

Science translational medicine, 2020-04, Vol.12 (541)

2020

Volltextzugriff (PDF)

Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy

Current drug metabolism, 2020-01, Vol.21 (2), p.145-162

2020

Volltextzugriff (PDF)

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes

Molecular pharmaceutics, 2022-01, Vol.19 (1), p.172-187

2022

Volltextzugriff (PDF)

Developing PreDICT – a fully integrated data platform for preclinical in vivo data: learning from experience

Drug discovery today, 2017-10, Vol.22 (10), p.1539-1546

2017

Volltextzugriff (PDF)

Model-based drug discovery: implementation and impact

Drug discovery today, 2013-08, Vol.18 (15-16), p.764-775

2013

Volltextzugriff (PDF)

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

Molecular cancer therapeutics, 2013-09, Vol.12 (9), p.1715-1727

2013

Volltextzugriff (PDF)

Abstract 3777: Applying mechanistic pharmacokinetic-pharmacodynamic models (PKPD) to describe the growth and inhibition of xenograft tumors in rats and mice by targeted anticancer agents

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3777-3777

2012

Volltextzugriff (PDF)

SASH WINDOWS

Notes and queries, 1912-03, Vol.s11-V (116), p.218-d-218

Bayley, A. R.

1912

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(15)
Pharmacology & Pharmacy
(13)
Animals
(12)
Pharmacokinetics
(7)
Models, Biological
(6)
Drug Discovery
(5)
Drug Discovery - Methods
(5)
Mice
(5)
Oncology
(5)
Chemistry, Medicinal
(4)
Disease Models, Animal
(4)
Physical Sciences
(4)
Absorption
(3)
Administration, Oral
(3)
Antineoplastic Agents - Pharmacology
(3)
Cell Line, Tumor
(3)
Chemistry
(3)
Distribution
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model

Interspecies evaluation of a physiologically based pharmacokinetic model to predict the biodistribution dynamics of dendritic nanoparticles

Discovery of N‑(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)‑1H‑1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors

Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes

Developing PreDICT – a fully integrated data platform for preclinical in vivo data: learning from experience

Model-based drug discovery: implementation and impact

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

Abstract 3777: Applying mechanistic pharmacokinetic-pharmacodynamic models (PKPD) to describe the growth and inhibition of xenograft tumors in rats and mice by targeted anticancer agents

SASH WINDOWS

Suchergebnisse filtern